Literature DB >> 10722611

Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers.

H Angelakopoulos1, E L Hohmann.   

Abstract

Attenuated Salmonella enterica serovar Typhi has been studied as an oral vaccine vector. Despite success with attenuated S. enterica serovar Typhimurium vectors in animals, early clinical trials of S. enterica serovar Typhi expressing heterologous antigens have shown that few subjects have detectable immune responses to vectored antigens. A previous clinical study of phoP/phoQ-deleted S. enterica serovar Typhi expressing Helicobacter pylori urease from a multicopy plasmid showed that none of eight subjects had detectable immune responses to the vectored antigen. In an attempt to further define the variables important for engendering immune responses to vectored antigens in humans, six volunteers were inoculated with 5 x 10(7) to 8 x 10(7) CFU of phoP/phoQ-deleted S. enterica serovar Typhimurium expressing the same antigen. Two of the six volunteers had fever; none had diarrhea, bacteremia, or other serious side effects. The volunteers were more durably colonized than in previous studies of phoP/phoQ-deleted S. enterica serovar Typhi. Five of the six volunteers seroconverted to S. enterica serovar Typhimurium antigens and had strong evidence of anti-Salmonella mucosal immune responses by enzyme-linked immunospot studies. Three of six (three of five who seroconverted to Salmonella) had immune responses in the most sensitive assay of urease-specific immunoglobulin production by blood mononuclear cells in vitro. One of these had a fourfold or greater increase in end-point immunoglobulin titer in serum versus urease. Attenuated S. enterica serovar Typhimurium appears to be more effective than S. enterica serovar Typhi for engendering immune responses to urease. Data suggest that this may be related to a greater stability of antigen-expressing plasmid in S. enterica serovar Typhimurium and/or prolonged intestinal colonization. Specific factors unique to nontyphoidal salmonellae may also be important for stimulation of the gastrointestinal immune system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722611      PMCID: PMC97395          DOI: 10.1128/IAI.68.4.2135-2141.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

Authors:  M M Levine; J B Kaper; D Herrington; J Ketley; G Losonsky; C O Tacket; B Tall; S Cryz
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

Review 2.  Typhoid fever: pathogenesis and immunologic control.

Authors:  R B Hornick; S E Greisman; T E Woodward; H L DuPont; A T Dawkins; M J Snyder
Journal:  N Engl J Med       Date:  1970-09-24       Impact factor: 91.245

3.  Identification of an intestinal immune response using peripheral blood lymphocytes.

Authors:  B D Forrest
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

4.  A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans.

Authors:  D M Hone; S R Attridge; B Forrest; R Morona; D Daniels; J T LaBrooy; R C Bartholomeusz; D J Shearman; J Hackett
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

5.  A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence.

Authors:  S I Miller; A M Kukral; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

6.  Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin, or placebo.

Authors:  J D Nelson; H Kusmiesz; L H Jackson; E Woodman
Journal:  Pediatrics       Date:  1980-06       Impact factor: 7.124

Review 7.  A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella.

Authors:  D S Buchwald; M J Blaser
Journal:  Rev Infect Dis       Date:  1984 May-Jun

8.  Method for the isolation of highly purified Salmonella flagellins.

Authors:  G F Ibrahim; G H Fleet; M J Lyons; R A Walker
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

9.  phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

Authors:  E L Hohmann; C A Oletta; K P Killeen; S I Miller
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

10.  Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.

Authors:  E L Hohmann; C A Oletta; S I Miller
Journal:  Vaccine       Date:  1996-01       Impact factor: 3.641

View more
  45 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development.

Authors:  Li-Mei Chen; Gabriel Briones; Ruben O Donis; Jorge E Galán
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

3.  Stabilization of a plasmid coding for a heterologous antigen in Salmonella enterica serotype typhi vaccine strain CVD908-htrA by using site-specific recombination.

Authors:  Jonathan C Stephens; Michael J Darsley; Arthur K Turner
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Homology modeling, molecular dynamics and QM/MM study of the regulatory protein PhoP from Corynebacterium pseudotuberculosis.

Authors:  Gleiciane Moraes; Vasco Azevedo; Marcília Costa; Anderson Miyoshi; Artur Silva; Vivian da Silva; Diana de Oliveira; Maria Fátima Teixeira; Jerônimo Lameira; Cláudio Nahum Alves
Journal:  J Mol Model       Date:  2011-06-24       Impact factor: 1.810

Review 5.  Salmonella as a vaccine delivery vehicle.

Authors:  Kenneth L Roland; Karen E Brenneman
Journal:  Expert Rev Vaccines       Date:  2013-09       Impact factor: 5.217

6.  Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines.

Authors:  Tie Liu; Rolf König; Jian Sha; Stacy L Agar; Chien-Te K Tseng; Gary R Klimpel; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-06       Impact factor: 3.738

7.  Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein.

Authors:  Lindsay J Hall; Simon Clare; Derek Pickard; Simon O Clark; Dominic L F Kelly; Moataz Abd El Ghany; Christine Hale; Jes Dietrich; Peter Andersen; Philip D Marsh; Gordon Dougan
Journal:  Vaccine       Date:  2009-09-13       Impact factor: 3.641

8.  Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.

Authors:  Huoying Shi; Javier Santander; Karen E Brenneman; Soo-Young Wanda; Shifeng Wang; Patti Senechal; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

9.  The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea.

Authors:  Kathrin Endt; Bärbel Stecher; Samuel Chaffron; Emma Slack; Nicolas Tchitchek; Arndt Benecke; Laurye Van Maele; Jean-Claude Sirard; Andreas J Mueller; Mathias Heikenwalder; Andrew J Macpherson; Richard Strugnell; Christian von Mering; Wolf-Dietrich Hardt
Journal:  PLoS Pathog       Date:  2010-09-09       Impact factor: 6.823

10.  Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains.

Authors:  Konstantin Rizos; Claus T Lattemann; Dirk Bumann; Thomas F Meyer; Toni Aebischer
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.